CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
REVENUES:
Grant income	$ 1,109	$ 1,466	$ 3,346	$ 3,596
Royalties from product sales and license fees	177	357	463	631
Subscription and advertisement revenues	69	343	700	1,020
Sale of research products and services	144	140	331	328
Total revenues	1,499	2,306	4,840	5,575
Cost of sales	(58)	(432)	(378)	(957)
Gross Profit	1,441	1,874	4,462	4,618
OPERATING EXPENSES:
Research and development	(6,422)	(11,433)	(29,093)	(29,816)
General and administrative	(4,574)	(7,545)	(23,083)	(18,911)
Total operating expenses	(10,996)	(18,978)	(52,176)	(48,727)
Loss from operations	(9,555)	(17,104)	(47,714)	(44,109)
OTHER INCOME/(EXPENSES):
Interest income/(expense), net	(167)	(12)	(513)	(207)
BioTime's share of losses in equity method investment in Ascendance	(855)	0	(1,189)	0
Gain on deconsolidation of Asterias (Note 3)	0	0	49,048	0
Gain on equity method investment in Asterias at fair value (Note 4)	40,015	0	26,532	0
Other income/(expense), net	(173)	(573)	197	(408)
Total other income/(expense), net	38,820	(585)	74,075	(615)
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	29,265	(17,689)	26,361	(44,724)
Deferred income tax benefit	0	948	0	3,395
NET INCOME (LOSS)	29,265	(16,741)	26,361	(41,329)
Net loss attributable to non-controlling interest	1,934	3,115	12,286	7,762
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	31,199	(13,626)	38,647	(33,567)
Dividends on preferred shares	0	(363)	0	(415)
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 31,199	$ (13,989)	$ 38,647	$ (33,982)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ 0.30	$ (0.18)	$ 0.40	$ (0.43)
DILUTED (in dollars per share)	$ 0.30	$ (0.18)	$ 0.39	$ (0.43)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	102,711	79,224	95,484	78,619
DILUTED (in shares)	103,613	79,224	99,073	78,619